Literature DB >> 33971297

Re-Operative Aortic Arch Surgery in a Contemporary Series.

Xiaoying Lou1, Bradley G Leshnower1, Jose Binongo1, Ziv Beckerman2, LaRonica McPherson1, Edward P Chen3.   

Abstract

Re-operative aortic arch operations (REDO) following previous cardiac surgery are challenging procedures associated with significant morbidity and mortality. We investigated post-operative outcomes for patients undergoing REDO and identified risk-factors for mortality in a contemporary series. From 1/2005-6/2018, 365 consecutive patients at an academic center underwent REDO: 257 HEMIARCH and 108 COMPLETE arch (45 stage I elephant trunk, 63 total arch) replacements. Outcomes included mortality and major adverse events. Long-term survival was determined with Kaplan-Meier analysis, and risk-factors for mortality were assessed with Cox proportional hazards regression. Operative mortality for the entire cohort was 6.8%, and rates of stroke, cardiac arrest, and renal failure were 6.0%, 7.4%, and 10.4%. Compared to HEMIARCH, COMPLETE patients had an increased incidence of renal failure requiring dialysis (15.7% vs 8.2%, p = 0.031) and re-exploration for bleeding or delayed chest closure (19.4% vs. 11.7%, p = 0.051). Although operative mortality was similar in both cohorts, long-term follow-up mortality (38.0% vs 26.8%, p = 0.047) was higher among COMPLETE vs. HEMIARCH. Predictors of overall mortality among all-comers undergoing REDO included older age, low body surface area, endocarditis, ejection fraction <30%, emergent status of operation, extended cardiopulmonary bypass duration, intra-aortic balloon pump use, and a more extensive arch operation. Previous aortic surgery was not a risk-factor for mortality. Among all-comers undergoing REDO, survival was 81.4% at 1 year, 66.7% at 5 years, and 56.4% at 10 years of follow-up. While early postoperative outcomes are similar among HEMIARCH and COMPLETE, a more extensive arch-replacement is an independent risk-factor for overall mortality in REDO. Using appropriate clinical indications in the current era, REDO remains a viable option for selected patients. Published by Elsevier Inc.

Entities:  

Keywords:  Aortic surgery outcomes; Reoperative aortic arch surgery

Year:  2021        PMID: 33971297     DOI: 10.1053/j.semtcvs.2021.03.035

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  1 in total

1.  Postsurgical Thrombotic Microangiopathy and Deregulated Complement.

Authors:  Thijs T W van Herpt; Sjoerd A M E G Timmermans; Walther N K A van Mook; Bas C T van Bussel; Iwan C C van der Horst; Jos G Maessen; Ehsan Natour; Pieter van Paassen; Samuel Heuts
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.